Respiratory effects and amnesia after premedication with morphine or lorazepam.
Lorazepam, a new benzodiazepine, was compared with morphine for premedication. Ten patients received morphine 10 mg/70 kg i.m. and 10 received lorazepam 4 mg/70 kg i.m. Respiratory effects were assessed from the change in slope (S) and intercept (B) of the carbon dioxide response line, using a development of Read's rebreathing method. Morphine depressed S by 47% (P less than 0.01), but after lorazepam S increased by 27% (P less than 0.05), neither drug altering B significantly. In two volunteers lorazepam was assessed by both the rebreathing and the steady-state methods; after lorazepam S was smaller by the steady-state than by the rebreathing technique. The findings for lorazepam are consistent with the known effects of sleep on carbon dioxide sensitivity. Amnesia lasting 4-8 h occurred in all patients who received lorazepam so that pain and nausea during this period were not recalled, but no patient who received morphine experienced amnesia. We conclude that lorazepam merits further study, particularly where sedation without respiratory depression is needed, as in obstetrics, and where amnesia for uncomfortable procedures is required.
D000293:Adolescent; D000328:Adult; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008140:Lorazepam / Q000494:pharmacology*; D008297:Male; D008568:Memory / Q000187:drug effects*; D011939:Mental Recall; D009020:Morphine / Q000494:pharmacology*; D011229:Preanesthetic Medication; D012018:Reflex / Q000187:drug effects; D012119:Respiration / Q000187:drug effects*
D014151:Anti-Anxiety Agents; D009020:Morphine; D008140:Lorazepam